THE EFFECTS OF SLEEP DEPRIVATION ON SPATIAL MEMORY, DREAM AND HYPERPHOSPHORYLATED TAU PROTEINS EXPRESSION IN RATS

NORHIDA BINTI RAMLI

UNIVERSITI SAINS MALAYSIA

2021

THE EFFECTS OF SLEEP DEPRIVATION ON SPATIAL MEMORY, DREAM AND HYPERPHOSPHORYLATED TAU PROTEINS EXPRESSION IN RATS

by

NORHIDA BINTI RAMLI

Thesis submitted in fulfilment of the requirements for the Degree of Doctor of Philosophy

MARCH 2021

ACKNOWLEDGEMENTS

In the name of ALLAH the Most Merciful and the Most Compassionate.

First, I would like to thank ALLAH for everything, without which, I won't be able to breathe on my own, let alone completing this research and writing.

For the most honourable supervisors, Dr Idris Long and Prof Dr Zalina Ismail, I would like to express the deepest gratitude for their patience, guidance, encouragement and lifelong guidance in this never ending endeavour, learning and researching. I pray to ALLAH the greatest blessing for them in this world and hereafter.

The largest appreciation to my late father, Mr Ramli Zain, my supportive mother, Mrs Aisah Kudsi, and my dear husband, Dr Mohd Anuar Ramdhan bin Ibrahim, my children, Wafaa, Fawwaz, Ziyaad, Adeena and the whole family for their continuous support and care.

Not to forget my thankfulness to my colleagues in Brainetwork Center PPSK, U.S.M., whom I believed are now successful person of their own organisation, for their help and guidance during my research works. Thank you too to all staffs in PPSK USM and Animal House U.S.M. for all their helps.

Finally, the biggest thanks to Universiti Sains Malaysia for the change given to me as a student in this degree. This research project was financially supported by USM Research grant. [1001.PSKBP.8630021].

ii

TABLE OF CONTENTS

ACK	NOWL	EDGEMENTS	ii
TAB	LE OF	CONTENTS	iii
LIST	OF TA	BLES	viii
LIST	OF FI	GURES	ix
LIST	OF AP	PENDICES	xii
LIST	OF AB	BREVIATIONS	xiii
ABS	ГRAK		xvii
ABS	ГRACT		XX
СНА	PTER 1	I INTRODUCTION	1
1.1	Ration	nale of The Study	2
1.2	Gener	al Objective	2
1.3	Specif	fic Objectives	2
СНА	PTER 2	2 LITERATURE REVIEW	3
2.1	Sleep		3
	2.1.1	Stages of Sleep, REM Sleep Versus NREM Sleep	3
	2.1.2	Physiological Benefits of Sleep	9
	2.1.3	Sleep-Wake – Regulating System	10
	2.1.4	Neuromodulator for Wake-Sleep Cycle	11
	2.1.5	Sleep Initiation Process	12
2.2	2.2 Circadian rhythm		13
	2.2.1	The molecular event under the circadian rhythm regulation	13
	2.2.2	Zeitgeber time	14
2.3	Memo	bry	14
	2.3.1	Memory classification	15
	2.3.2	Memory Stages	17
	2.3.3	Cellular and Molecular Level of Memory Formation	17
2.4	Sleep	and Memory	21
	2.4.1	Roles of Sleep on Memory Consolidation	21
	2.4.2	Molecular Modulator for LTP in Memory Consolidation	22
2.5	Circae	lian Rhythm and Memory	24

 2.6.1 Hippocampal formation 2.6.2 Hippocampal Neuronal Circuit 2.6.3 Hippocampal Neural Complex and Memory 2.7 DREAM Protein 2.7.1 Role of DREAM Protein 2.7.2 DREAM Protein in Learning and Memory 2.8 Tau Protein 2.8.1 Tau Structure 2.8.2 Neurodegenerative Disease and Tau Protein Properties. 2.8.3 Paired Helical Filament (PHF) 2.8.4 Roles of Tau Protein in The Pathogenesis of Neurodegenerative Diseases 2.8.5 Tau Phosphorylation and It's Regulation. 2.8.6 Clinical Manifestation of Hyperphosphorylation of Tau Protei 2.9 Neurobehavioral Analysis Involving Animal 2.9.1 Morris Water Maze Analysis of Spatial Memory CHAPTER 3 MATERIALS AND METHODS 3.1 Materials 3.2 Preparation of Solutions 3.2.1 Ammonium Persulphate (APS) (20%) 3.2.2 Diaminobenzidine (DAB) 3.2.3 Loading Buffer 3.2.4 Ponceau S 3.2.5 Phosphate-buffered Saline (PBS) pH 7.4 3.2.6 Phosphate Buffer (PB) Stock (0.2 M) 3.2.7 Paraformaldehyde (PFA) (4%) in 0.1 M PB pH 7.4 3.2.9 Resolving Buffer 3.2.10 Running Buffer 3.2.11 Stacking Buffer 3.2.12 Sample Buffer 3.2.13 Sucrose (20%) in 0.1 M PB pH 7.4 3.2.14 Trizma Base Stock Buffer 	2.6	Hippo	campus and Memory	24
 2.6.2 Hippocampal Neuronal Circuit 2.6.3 Hippocampal Neural Complex and Memory 2.7 DREAM Protein 2.7.1 Role of DREAM Protein 2.7.2 DREAM Protein in Learning and Memory 2.8 Tau Protein 2.8.1 Tau Structure 2.8.2 Neurodegenerative Disease and Tau Protein Properties. 2.8.3 Paired Helical Filament (PHF) 2.8.4 Roles of Tau Protein in The Pathogenesis of Neurodegenerative Diseases 2.8.5 Tau Phosphorylation and It's Regulation. 2.8.6 Clinical Manifestation of Hyperphosphorylation of Tau Protei 2.9 Neurobehavioral Analysis Involving Animal 2.9.1 Morris Water Maze Analysis of Spatial Memory CHAPTER 3 MATERIALS AND METHODS 3.1 Materials 3.2 Preparation of Solutions 3.2.1 Ammonium Persulphate (APS) (20%) 3.2.2 Diaminobenzidine (DAB) 3.2.3 Loading Buffer 3.2.4 Ponceau S 3.2.5 Phosphate-buffered Saline (PBS) pH 7.4 3.2.6 Phosphate Buffer (PB) Stock (0.2 M) 3.2.7 Paraformaldehyde Stock (8%) 3.2.8 Paraformaldehyde (PFA) (4%) in 0.1 M PB pH 7.4 3.2.9 Resolving Buffer 3.2.10 Running Buffer 3.2.12 Sample Buffer 3.2.13 Sucrose (20%) in 0.1 M PB pH 7.4 3.2.14 Trizma Base Stock Buffer 		2.6.1	Hippocampal formation	26
 2.6.3 Hippocampal Neural Complex and Memory 2.7 DREAM Protein 2.7.1 Role of DREAM Protein 2.7.2 DREAM Protein in Learning and Memory 2.8 Tau Protein 2.8.1 Tau Structure 2.8.2 Neurodegenerative Disease and Tau Protein Properties. 2.8.3 Paired Helical Filament (PHF) 2.8.4 Roles of Tau Protein in The Pathogenesis of Neurodegenerative Diseases 2.8.5 Tau Phosphorylation and It's Regulation. 2.8.6 Clinical Manifestation of Hyperphosphorylation of Tau Protei 2.9 Neurobehavioral Analysis Involving Animal 2.9.1 Morris Water Maze Analysis of Spatial Memory CHAPTER 3 MATERIALS AND METHODS 3.1 Materials 3.2 Preparation of Solutions 3.2.1 Ammonium Persulphate (APS) (20%) 3.2.2 Diaminobenzidine (DAB) 3.2.3 Loading Buffer 3.2.4 Ponceau S 3.2.5 Phosphate-buffered Saline (PBS) pH 7.4 3.2.6 Phosphate Buffer (PB) Stock (0.2 M) 3.2.7 Paraformaldehyde Stock (8%) 3.2.8 Paraformaldehyde (PFA) (4%) in 0.1 M PB pH 7.4 3.2.9 Resolving Buffer 3.2.10 Running Buffer 3.2.11 Stacking Buffer 3.2.12 Sample Buffer 3.2.13 Sucrose (20%) in 0.1 M PB pH 7.4 3.2.14 Trizma Base Stock Buffer 		2.6.2	Hippocampal Neuronal Circuit	28
 2.7 DREAM Protein 2.7.1 Role of DREAM Protein 2.7.2 DREAM Protein in Learning and Memory 2.8 Tau Protein 2.8.1 Tau Structure 2.8.2 Neurodegenerative Disease and Tau Protein Properties. 2.8.3 Paired Helical Filament (PHF) 2.8.4 Roles of Tau Protein in The Pathogenesis of Neurodegenerative Diseases 2.8.5 Tau Phosphorylation and It's Regulation. 2.8.6 Clinical Manifestation of Hyperphosphorylation of Tau Protei 2.9 Neurobehavioral Analysis Involving Animal 2.9.1 Morris Water Maze Analysis of Spatial Memory CHAPTER 3 MATERIALS AND METHODS 3.1 Materials 3.2 Preparation of Solutions 3.2.1 Ammonium Persulphate (APS) (20%) 3.2.2 Diaminobenzidine (DAB) 3.2.3 Loading Buffer 3.2.4 Ponceau S 3.2.5 Phosphate-buffered Saline (PBS) pH 7.4 3.2.6 Phosphate Buffer (PB) Stock (0.2 M) 3.2.7 Paraformaldehyde Stock (8%) 3.2.8 Paraformaldehyde (PFA) (4%) in 0.1 M PB pH 7.4 3.2.10 Running Buffer 3.2.11 Stacking Buffer 3.2.12 Sample Buffer 3.2.13 Sucrose (20%) in 0.1 M PB pH 7.4 3.2.14 Trizma Base Stock Buffer 		2.6.3	Hippocampal Neural Complex and Memory	30
 2.7.1 Role of DREAM Protein 2.7.2 DREAM Protein in Learning and Memory 2.8 Tau Protein 2.8.1 Tau Structure 2.8.2 Neurodegenerative Disease and Tau Protein Properties. 2.8.3 Paired Helical Filament (PHF) 2.8.4 Roles of Tau Protein in The Pathogenesis of Neurodegenerative Diseases 2.8.5 Tau Phosphorylation and It's Regulation. 2.8.6 Clinical Manifestation of Hyperphosphorylation of Tau Protei 2.9 Neurobehavioral Analysis Involving Animal 2.9.1 Morris Water Maze Analysis of Spatial Memory CHAPTER 3 MATERIALS AND METHODS 3.1 Materials 3.2 Preparation of Solutions 3.2.1 Ammonium Persulphate (APS) (20%) 3.2.2 Diaminobenzidine (DAB) 3.2.3 Loading Buffer 3.2.4 Ponceau S 3.2.5 Phosphate-buffered Saline (PBS) pH 7.4 3.2.6 Phosphate Buffer (PB) Stock (0.2 M) 3.2.7 Paraformaldehyde (PFA) (4%) in 0.1 M PB pH 7.4 3.2.9 Resolving Buffer 3.2.10 Running Buffer 3.2.11 Stacking Buffer 3.2.12 Sample Buffer 3.2.13 Sucrose (20%) in 0.1 M PB pH 7.4 3.2.14 Trizma Base Stock Buffer 	2.7	DREA	M Protein	32
 2.7.2 DREAM Protein in Learning and Memory 2.8 Tau Protein 2.8.1 Tau Structure 2.8.2 Neurodegenerative Disease and Tau Protein Properties. 2.8.3 Paired Helical Filament (PHF) 2.8.4 Roles of Tau Protein in The Pathogenesis of Neurodegenerative Diseases 2.8.5 Tau Phosphorylation and It's Regulation. 2.8.6 Clinical Manifestation of Hyperphosphorylation of Tau Protei 2.9 Neurobehavioral Analysis Involving Animal 2.9.1 Morris Water Maze Analysis of Spatial Memory CHAPTER 3 MATERIALS AND METHODS 3.1 Materials 3.2 Preparation of Solutions 3.2.1 Ammonium Persulphate (APS) (20%) 3.2.2 Diaminobenzidine (DAB) 3.2.3 Loading Buffer 3.2.4 Ponceau S 3.2.5 Phosphate-buffered Saline (PBS) pH 7.4 3.2.6 Phosphate Buffer (PB) Stock (0.2 M) 3.2.7 Paraformaldehyde Stock (8%) 3.2.8 Paraformaldehyde (PFA) (4%) in 0.1 M PB pH 7.4 3.2.10 Running Buffer 3.2.11 Stacking Buffer 3.2.12 Sample Buffer 3.2.13 Sucrose (20%) in 0.1 M PB pH 7.4 3.2.14 Trizma Base Stock Buffer 		2.7.1	Role of DREAM Protein	33
 2.8 Tau Protein 2.8.1 Tau Structure 2.8.2 Neurodegenerative Disease and Tau Protein Properties. 2.8.3 Paired Helical Filament (PHF) 2.8.4 Roles of Tau Protein in The Pathogenesis of Neurodegenerative Diseases 2.8.5 Tau Phosphorylation and It's Regulation. 2.8.6 Clinical Manifestation of Hyperphosphorylation of Tau Protei 2.9 Neurobehavioral Analysis Involving Animal 2.9.1 Morris Water Maze Analysis of Spatial Memory CHAPTER 3 MATERIALS AND METHODS 3.1 Materials 3.2 Preparation of Solutions 3.2.1 Ammonium Persulphate (APS) (20%) 3.2.2 Diaminobenzidine (DAB) 3.2.3 Loading Buffer 3.2.4 Ponceau S 3.2.5 Phosphate-buffered Saline (PBS) pH 7.4 3.2.6 Phosphate Buffer (PB) Stock (0.2 M) 3.2.7 Paraformaldehyde Stock (8%) 3.2.8 Paraformaldehyde (PFA) (4%) in 0.1 M PB pH 7.4 3.2.9 Resolving Buffer 3.2.11 Stacking Buffer 3.2.12 Sample Buffer 3.2.13 Sucrose (20%) in 0.1 M PB pH 7.4 3.2.14 Trizma Base Stock Buffer 		2.7.2	DREAM Protein in Learning and Memory	36
 2.8.1 Tau Structure 2.8.2 Neurodegenerative Disease and Tau Protein Properties. 2.8.3 Paired Helical Filament (PHF) 2.8.4 Roles of Tau Protein in The Pathogenesis of Neurodegenerative Diseases 2.8.5 Tau Phosphorylation and It's Regulation. 2.8.6 Clinical Manifestation of Hyperphosphorylation of Tau Protei 2.9 Neurobehavioral Analysis Involving Animal 2.9.1 Morris Water Maze Analysis of Spatial Memory CHAPTER 3 MATERIALS AND METHODS 3.1 Materials 3.2 Preparation of Solutions 3.2.1 Ammonium Persulphate (APS) (20%) 3.2.2 Diaminobenzidine (DAB) 3.2.3 Loading Buffer 3.2.4 Ponceau S 3.2.5 Phosphate-buffered Saline (PBS) pH 7.4 3.2.6 Phosphate Buffer (PB) Stock (0.2 M) 3.2.7 Paraformaldehyde Stock (8%) 3.2.8 Paraformaldehyde (PFA) (4%) in 0.1 M PB pH 7.4 3.2.9 Resolving Buffer 3.2.11 Stacking Buffer 3.2.12 Sample Buffer 3.2.13 Sucrose (20%) in 0.1 M PB pH 7.4 3.2.14 Trizma Base Stock Buffer 	2.8	Tau Pr	otein	36
 2.8.2 Neurodegenerative Disease and Tau Protein Properties. 2.8.3 Paired Helical Filament (PHF) 2.8.4 Roles of Tau Protein in The Pathogenesis of Neurodegenerative Diseases 2.8.5 Tau Phosphorylation and It's Regulation. 2.8.6 Clinical Manifestation of Hyperphosphorylation of Tau Protein 2.9 Neurobehavioral Analysis Involving Animal 2.9.1 Morris Water Maze Analysis of Spatial Memory CHAPTER 3 MATERIALS AND METHODS 3.1 Materials 3.2 Preparation of Solutions 3.2.1 Ammonium Persulphate (APS) (20%) 3.2.2 Diaminobenzidine (DAB) 3.2.3 Loading Buffer 3.2.4 Ponceau S 3.2.5 Phosphate-buffered Saline (PBS) pH 7.4 3.2.6 Phosphate Buffer (PB) Stock (0.2 M) 3.2.7 Paraformaldehyde (PFA) (4%) in 0.1 M PB pH 7.4 3.2.9 Resolving Buffer 3.2.11 Stacking Buffer 3.2.12 Sample Buffer 3.2.13 Sucrose (20%) in 0.1 M PB pH 7.4 3.2.14 Trizma Base Stock Buffer 		2.8.1	Tau Structure	39
 2.8.3 Paired Helical Filament (PHF) 2.8.4 Roles of Tau Protein in The Pathogenesis of Neurodegenerative Diseases 2.8.5 Tau Phosphorylation and It's Regulation. 2.8.6 Clinical Manifestation of Hyperphosphorylation of Tau Protein 2.9 Neurobehavioral Analysis Involving Animal 2.9.1 Morris Water Maze Analysis of Spatial Memory CHAPTER 3 MATERIALS AND METHODS 3.1 Materials 3.2 Preparation of Solutions 3.2.1 Ammonium Persulphate (APS) (20%) 3.2.2 Diaminobenzidine (DAB) 3.2.3 Loading Buffer 3.2.4 Ponceau S 3.2.5 Phosphate-buffered Saline (PBS) pH 7.4 3.2.6 Phosphate Buffer (PB) Stock (0.2 M) 3.2.7 Paraformaldehyde (PFA) (4%) in 0.1 M PB pH 7.4 3.2.9 Resolving Buffer 3.2.10 Running Buffer 3.2.11 Stacking Buffer 3.2.12 Sample Buffer 3.2.13 Sucrose (20%) in 0.1 M PB pH 7.4 3.214 Trizma Base Stock Buffer 		2.8.2	Neurodegenerative Disease and Tau Protein Properties.	41
 2.8.4 Roles of Tau Protein in The Pathogenesis of Neurodegenerative Diseases 2.8.5 Tau Phosphorylation and It's Regulation. 2.8.6 Clinical Manifestation of Hyperphosphorylation of Tau Protein 2.9 Neurobehavioral Analysis Involving Animal 2.9.1 Morris Water Maze Analysis of Spatial Memory CHAPTER 3 MATERIALS AND METHODS 3.1 Materials 3.2 Preparation of Solutions 3.2.1 Ammonium Persulphate (APS) (20%) 3.2.2 Diaminobenzidine (DAB) 3.2.3 Loading Buffer 3.2.4 Ponceau S 3.2.5 Phosphate-buffered Saline (PBS) pH 7.4 3.2.6 Phosphate Buffer (PB) Stock (0.2 M) 3.2.7 Paraformaldehyde Stock (8%) 3.2.8 Paraformaldehyde (PFA) (4%) in 0.1 M PB pH 7.4 3.2.9 Resolving Buffer 3.2.10 Running Buffer 3.2.11 Stacking Buffer 3.2.12 Sample Buffer 3.2.13 Sucrose (20%) in 0.1 M PB pH 7.4 3.2.14 Trizma Base Stock Buffer 		2.8.3	Paired Helical Filament (PHF)	41
Diseases2.8.5Tau Phosphorylation and It's Regulation.2.8.6Clinical Manifestation of Hyperphosphorylation of Tau Protei2.9Neurobehavioral Analysis Involving Animal2.9.1Morris Water Maze Analysis of Spatial MemoryCHAPTER 3 MATERIALS AND METHODS3.1Materials3.2Preparation of Solutions3.1.1Ammonium Persulphate (APS) (20%)3.2.2Diaminobenzidine (DAB)3.2.3Loading Buffer3.2.4Ponceau S3.2.5Phosphate-buffered Saline (PBS) pH 7.43.2.6Phosphate Buffer (PB) Stock (0.2 M)3.2.7Paraformaldehyde Stock (8%)3.2.8Paraformaldehyde (PFA) (4%) in 0.1 M PB pH 7.43.2.9Resolving Buffer3.2.11Stacking Buffer3.2.12Sample Buffer3.2.13Sucrose (20%) in 0.1 M PB pH 7.43.2.14Trizma Base Stock Buffer		2.8.4	Roles of Tau Protein in The Pathogenesis of Neurodegenerative	
 2.8.5 Tau Phosphorylation and It's Regulation. 2.8.6 Clinical Manifestation of Hyperphosphorylation of Tau Protei 2.9 Neurobehavioral Analysis Involving Animal 2.9.1 Morris Water Maze Analysis of Spatial Memory CHAPTER 3 MATERIALS AND METHODS 3.1 Materials 3.2 Preparation of Solutions 3.2.1 Ammonium Persulphate (APS) (20%) 3.2.2 Diaminobenzidine (DAB) 3.2.3 Loading Buffer 3.2.4 Ponceau S 3.2.5 Phosphate-buffered Saline (PBS) pH 7.4 3.2.6 Phosphate Buffer (PB) Stock (0.2 M) 3.2.7 Paraformaldehyde (PFA) (4%) in 0.1 M PB pH 7.4 3.2.9 Resolving Buffer 3.2.10 Running Buffer 3.2.11 Stacking Buffer 3.2.12 Sample Buffer 3.2.13 Sucrose (20%) in 0.1 M PB pH 7.4 3.2.14 Trizma Base Stock Buffer 			Diseases	44
 2.8.6 Clinical Manifestation of Hyperphosphorylation of Tau Protein 2.9 Neurobehavioral Analysis Involving Animal 2.9.1 Morris Water Maze Analysis of Spatial Memory CHAPTER 3 MATERIALS AND METHODS 3.1 Materials 3.2 Preparation of Solutions 3.2.1 Ammonium Persulphate (APS) (20%) 3.2.2 Diaminobenzidine (DAB) 3.2.3 Loading Buffer 3.2.4 Ponceau S 3.2.5 Phosphate-buffered Saline (PBS) pH 7.4 3.2.6 Phosphate Buffer (PB) Stock (0.2 M) 3.2.7 Paraformaldehyde Stock (8%) 3.2.8 Paraformaldehyde (PFA) (4%) in 0.1 M PB pH 7.4 3.2.9 Resolving Buffer 3.2.11 Stacking Buffer 3.2.12 Sample Buffer 3.2.13 Sucrose (20%) in 0.1 M PB pH 7.4 3.2.14 Trizma Base Stock Buffer 		2.8.5	Tau Phosphorylation and It's Regulation.	44
 2.9 Neurobehavioral Analysis Involving Animal 2.9.1 Morris Water Maze Analysis of Spatial Memory CHAPTER 3 MATERIALS AND METHODS 3.1 Materials 3.2 Preparation of Solutions 3.2.1 Ammonium Persulphate (APS) (20%) 3.2.2 Diaminobenzidine (DAB) 3.2.3 Loading Buffer 3.2.4 Ponceau S 3.2.5 Phosphate-buffered Saline (PBS) pH 7.4 3.2.6 Phosphate Buffer (PB) Stock (0.2 M) 3.2.7 Paraformaldehyde Stock (8%) 3.2.8 Paraformaldehyde (PFA) (4%) in 0.1 M PB pH 7.4 3.2.9 Resolving Buffer 3.2.11 Stacking Buffer 3.2.12 Sample Buffer 3.2.13 Sucrose (20%) in 0.1 M PB pH 7.4 3.2.14 Trizma Base Stock Buffer 		2.8.6	Clinical Manifestation of Hyperphosphorylation of Tau Protein.	46
 2.9.1 Morris Water Maze Analysis of Spatial Memory CHAPTER 3 MATERIALS AND METHODS 3.1 Materials 3.2 Preparation of Solutions 3.2.1 Ammonium Persulphate (APS) (20%) 3.2.2 Diaminobenzidine (DAB) 3.2.3 Loading Buffer 3.2.4 Ponceau S 3.2.5 Phosphate-buffered Saline (PBS) pH 7.4 3.2.6 Phosphate Buffer (PB) Stock (0.2 M) 3.2.7 Paraformaldehyde Stock (8%) 3.2.8 Paraformaldehyde (PFA) (4%) in 0.1 M PB pH 7.4 3.2.9 Resolving Buffer 3.2.10 Running Buffer 3.2.11 Stacking Buffer 3.2.12 Sample Buffer 3.2.13 Sucrose (20%) in 0.1 M PB pH 7.4 3.2.14 Trizma Base Stock Buffer 	2.9	Neurol	behavioral Analysis Involving Animal	47
 CHAPTER 3 MATERIALS AND METHODS 3.1 Materials 3.2 Preparation of Solutions 3.2.1 Ammonium Persulphate (APS) (20%) 3.2.2 Diaminobenzidine (DAB) 3.2.3 Loading Buffer 3.2.4 Ponceau S 3.2.5 Phosphate-buffered Saline (PBS) pH 7.4 3.2.6 Phosphate Buffer (PB) Stock (0.2 M) 3.2.7 Paraformaldehyde Stock (8%) 3.2.8 Paraformaldehyde (PFA) (4%) in 0.1 M PB pH 7.4 3.2.9 Resolving Buffer 3.2.10 Running Buffer 3.2.11 Stacking Buffer 3.2.12 Sample Buffer 3.2.13 Sucrose (20%) in 0.1 M PB pH 7.4 3.2.14 Trizma Base Stock Buffer 		2.9.1	Morris Water Maze Analysis of Spatial Memory	47
 3.1 Materials 3.2 Preparation of Solutions 3.2.1 Ammonium Persulphate (APS) (20%) 3.2.2 Diaminobenzidine (DAB) 3.2.3 Loading Buffer 3.2.4 Ponceau S 3.2.5 Phosphate-buffered Saline (PBS) pH 7.4 3.2.6 Phosphate Buffer (PB) Stock (0.2 M) 3.2.7 Paraformaldehyde Stock (8%) 3.2.8 Paraformaldehyde (PFA) (4%) in 0.1 M PB pH 7.4 3.2.9 Resolving Buffer 3.2.10 Running Buffer 3.2.12 Sample Buffer 3.2.13 Sucrose (20%) in 0.1 M PB pH 7.4 3.2.14 Trizma Base Stock Buffer 	CHAI	PTER 3	MATERIALS AND METHODS	50
 3.2 Preparation of Solutions 3.2.1 Ammonium Persulphate (APS) (20%) 3.2.2 Diaminobenzidine (DAB) 3.2.3 Loading Buffer 3.2.4 Ponceau S 3.2.5 Phosphate-buffered Saline (PBS) pH 7.4 3.2.6 Phosphate Buffer (PB) Stock (0.2 M) 3.2.7 Paraformaldehyde Stock (8%) 3.2.8 Paraformaldehyde (PFA) (4%) in 0.1 M PB pH 7.4 3.2.9 Resolving Buffer 3.2.10 Running Buffer 3.2.11 Stacking Buffer 3.2.12 Sample Buffer 3.2.13 Sucrose (20%) in 0.1 M PB pH 7.4 3.2.14 Trizma Base Stock Buffer 	3.1	Materials		50
 3.2.1 Ammonium Persulphate (APS) (20%) 3.2.2 Diaminobenzidine (DAB) 3.2.3 Loading Buffer 3.2.4 Ponceau S 3.2.5 Phosphate-buffered Saline (PBS) pH 7.4 3.2.6 Phosphate Buffer (PB) Stock (0.2 M) 3.2.7 Paraformaldehyde Stock (8%) 3.2.8 Paraformaldehyde (PFA) (4%) in 0.1 M PB pH 7.4 3.2.9 Resolving Buffer 3.2.10 Running Buffer 3.2.11 Stacking Buffer 3.2.12 Sample Buffer 3.2.13 Sucrose (20%) in 0.1 M PB pH 7.4 3.2.14 Trizma Base Stock Buffer 	3.2	Prepar	ation of Solutions	50
 3.2.2 Diaminobenzidine (DAB) 3.2.3 Loading Buffer 3.2.4 Ponceau S 3.2.5 Phosphate-buffered Saline (PBS) pH 7.4 3.2.6 Phosphate Buffer (PB) Stock (0.2 M) 3.2.7 Paraformaldehyde Stock (8%) 3.2.8 Paraformaldehyde (PFA) (4%) in 0.1 M PB pH 7.4 3.2.9 Resolving Buffer 3.2.10 Running Buffer 3.2.11 Stacking Buffer 3.2.12 Sample Buffer 3.2.13 Sucrose (20%) in 0.1 M PB pH 7.4 3.2.14 Trizma Base Stock Buffer 		3.2.1	Ammonium Persulphate (APS) (20%)	50
 3.2.3 Loading Buffer 3.2.4 Ponceau S 3.2.5 Phosphate-buffered Saline (PBS) pH 7.4 3.2.6 Phosphate Buffer (PB) Stock (0.2 M) 3.2.7 Paraformaldehyde Stock (8%) 3.2.8 Paraformaldehyde (PFA) (4%) in 0.1 M PB pH 7.4 3.2.9 Resolving Buffer 3.2.10 Running Buffer 3.2.11 Stacking Buffer 3.2.12 Sample Buffer 3.2.13 Sucrose (20%) in 0.1 M PB pH 7.4 3.2.14 Trizma Base Stock Buffer 		3.2.2	Diaminobenzidine (DAB)	50
 3.2.4 Ponceau S 3.2.5 Phosphate-buffered Saline (PBS) pH 7.4 3.2.6 Phosphate Buffer (PB) Stock (0.2 M) 3.2.7 Paraformaldehyde Stock (8%) 3.2.8 Paraformaldehyde (PFA) (4%) in 0.1 M PB pH 7.4 3.2.9 Resolving Buffer 3.2.10 Running Buffer 3.2.11 Stacking Buffer 3.2.12 Sample Buffer 3.2.13 Sucrose (20%) in 0.1 M PB pH 7.4 3.2.14 Trizma Base Stock Buffer 		3.2.3	Loading Buffer	51
 3.2.5 Phosphate-buffered Saline (PBS) pH 7.4 3.2.6 Phosphate Buffer (PB) Stock (0.2 M) 3.2.7 Paraformaldehyde Stock (8%) 3.2.8 Paraformaldehyde (PFA) (4%) in 0.1 M PB pH 7.4 3.2.9 Resolving Buffer 3.2.10 Running Buffer 3.2.11 Stacking Buffer 3.2.12 Sample Buffer 3.2.13 Sucrose (20%) in 0.1 M PB pH 7.4 3.2.14 Trizma Base Stock Buffer 		3.2.4	Ponceau S	51
 3.2.6 Phosphate Buffer (PB) Stock (0.2 M) 3.2.7 Paraformaldehyde Stock (8%) 3.2.8 Paraformaldehyde (PFA) (4%) in 0.1 M PB pH 7.4 3.2.9 Resolving Buffer 3.2.10 Running Buffer 3.2.11 Stacking Buffer 3.2.12 Sample Buffer 3.2.13 Sucrose (20%) in 0.1 M PB pH 7.4 3.2.14 Trizma Base Stock Buffer 		3.2.5	Phosphate-buffered Saline (PBS) pH 7.4	51
 3.2.7 Paraformaldehyde Stock (8%) 3.2.8 Paraformaldehyde (PFA) (4%) in 0.1 M PB pH 7.4 3.2.9 Resolving Buffer 3.2.10 Running Buffer 3.2.11 Stacking Buffer 3.2.12 Sample Buffer 3.2.13 Sucrose (20%) in 0.1 M PB pH 7.4 3.2.14 Trizma Base Stock Buffer 		3.2.6	Phosphate Buffer (PB) Stock (0.2 M)	51
 3.2.8 Paraformaldehyde (PFA) (4%) in 0.1 M PB pH 7.4 3.2.9 Resolving Buffer 3.2.10 Running Buffer 3.2.11 Stacking Buffer 3.2.12 Sample Buffer 3.2.13 Sucrose (20%) in 0.1 M PB pH 7.4 3.2.14 Trizma Base Stock Buffer 		3.2.7	Paraformaldehyde Stock (8%)	52
 3.2.9 Resolving Buffer 3.2.10 Running Buffer 3.2.11 Stacking Buffer 3.2.12 Sample Buffer 3.2.13 Sucrose (20%) in 0.1 M PB pH 7.4 3.2.14 Trizma Base Stock Buffer 		3.2.8	Paraformaldehyde (PFA) (4%) in 0.1 M PB pH 7.4	52
 3.2.10 Running Buffer 3.2.11 Stacking Buffer 3.2.12 Sample Buffer 3.2.13 Sucrose (20%) in 0.1 M PB pH 7.4 3.2.14 Trizma Base Stock Buffer 		3.2.9	Resolving Buffer	52
 3.2.11 Stacking Buffer 3.2.12 Sample Buffer 3.2.13 Sucrose (20%) in 0.1 M PB pH 7.4 3.2.14 Trizma Base Stock Buffer 		3.2.10	Running Buffer	52
3.2.12 Sample Buffer3.2.13 Sucrose (20%) in 0.1 M PB pH 7.43.2.14 Trizma Base Stock Buffer		3.2.11	Stacking Buffer	52
3.2.13 Sucrose (20%) in 0.1 M PB pH 7.43.2.14 Trizma Base Stock Buffer		3.2.12	Sample Buffer	53
3.2.14 Trizma Base Stock Buffer		3.2.13	Sucrose (20%) in 0.1 M PB pH 7.4	53
		3.2.14	Trizma Base Stock Buffer	53

	3.2.15	Tris-buffered Saline (TBS) pH 7.4	53
	3.2.16	Tris-triton (TBS/TX) pH 7.4	53
	3.2.17	Transfer Buffer	53
	3.2.18	Tris Buffer Saline (TBST)	54
	3.2.19	Tris Buffer Saline-Tween 20 (TBS-T20) (0.05%)	54
3.3	Anima	als Preparation	54
	3.3.1	Sample Size for Animal Study.	54
	3.3.2	Experimental Groups	55
	3.3.3	Circadian disruption experiment	58
	3.3.4	REM Sleep Experiment	61
3.4	Morris	s Water Maze	65
	3.4.1	Equipment for Morris Water Maze	65
	3.4.2	Morris Water Maze Procedure	65
3.5	Immu	nohistochemistry for DREAM, Tau, and Hyperhosphorylated Tau	
	Protein	ns.	69
	3.5.1	Brain sampling for Immunohistochemistry	69
	3.5.2	Brain Dissection and Cryostat Sectioning	69
	3.5.3	Preparation of DREAM, Tau, and Hyperphosphorylated Tau	
		Immunopositive Neurons	70
	3.5.4	Positive DREAM, Tau, and Hyperphosphorylated Tau Protein	
		Counting.	71
3.6	Weste	rn Blot Analysis	74
	3.6.1	Brain Sampling for Western Blot Analysis	74
	3.6.2	Protein Extraction for Western Blot Analysis	74
	3.6.3	Measurement of Protein Concentration	75
	3.6.4	Preparation of Sodium Dodecyl Sulphate Polyacrylamide gel (SI	DS-
		PAGE).	76
	3.6.5	Electrophoresis of SDS-PAGE gel	79
	3.6.6	Electrophoretic Transfer and Immunoblotting	79
	3.6.7	Measurement of Mean Relative Intensity (fold changes)	82
3.7	Statist	ical Analysis	83
CHA	PTER 4	RESULTS	85
4.1	Effects	s of REM Sleep Deprivation on Food Consumption and Body We	ight
	Gain.		85

	4.1.1	Food Consumption	85
	4.1.2	Body Weight Gain	87
4.2	Serum	Melatonin Level for Circadian Disruption Experiment.	89
4.3	Neuro	behavioral Analysis Using Morris Water Maze (MWM) Test.	91
	4.3.1	Spatial Learning and Memory.	91
	4.3.2	Probe test.	94
	4.3.3	Reverse Spatial.	96
4.4	Immu	nohistochemical Analysis	98
	4.4.1	Results of DREAM Positive Neuronal Cells (DPN)	98
	4.4.2	Hyperphosphorylated Tau Protein Expression.	102
4.5	Weste	rn Blot Analysis	109
	4.5.1	Mean Relative DREAM Protein Level in Hippocampal Nucleus.	109
	4.5.2	Mean Relative Phosphorylated Tau Protein Level in Hippocampa	1
		Nucleus.	112
	4.5.3	Mean Relative of Total Tau Protein in Hippocampal Nucleus.	115
	4.5.4	Mean Relative PPN / Total Tau Proteins Ratio.	118
	4.5.5	Mean Relative DREAM Protein Level in Hippocampal Cytoplasm	n.
			120
	4.5.6	Mean Relative Phosphorylated Tau Protein Level in Hippocampa	1
		Cytoplasm	123
	4.5.7	Mean Relative of Total Tau Protein in Hippocampal Cytoplasm.	126
	4.5.8	Mean Relative PPN Tau / Total Tau Proteins Ratio.	129
4.6	Summ	ary on Semi-Quantitative Analysis of Dream Protein Level in	
	Hippo	campal Neurons and Cytoplasm.	131
4.7	Summ	ary on Semi-Quantitative Analysis of Tau Protein Level, PPN Prot	tein
	Level,	and PPN/Tau Ratio in Hippocampal Neurons and Cytoplasm.	132
CHAI	PTER 5	DISCUSSION	134
5.1	Assess	sment of REMsd	134
5.2	Circac	lian Disruption Measurement.	136
5.3	Effect	s of REMsd and CD on MWM test.	137
	5.3.1	Effects of REMsd and CD on spatial learning MWM paradigm.	137
	5.3.2	Effects of REMsd and CD in probe test MWM paradigm.	139
	5.3.3	Effects of REMsd and CD on reversal spatial learning MWM	
		paradigm.	141

5.4	Effects of Remsd and CD on DREAM Protein Expression and Tau Protein		
	Hyper	phosphorylation.	144
	5.4.1	Effect of REMsd and CD on DREAM protein expression.	144
	5.4.2	Effects of REMsd and CD on Tau protein expression (TPN) and	
		hyperphosphorylated Tau positive neuron (PPN).	147
5.5	Summ	arization of Findings from This Study	150
CHAF	PTER 6	CONCLUSION, LIMITATION AND RECOMMENDATION	152
6.1	Conclu	ision	152
6.2	Limita	tion	152
6.3	Recon	nmendation	153
REFERENCES 154			
APPENDICES			
LIST	OF PR	ESENTATION AND PUBLICATION	

LIST OF TABLES

Page

Table 2.1	Brainwaves in different states of mind and stages of sleep.	8
Table 3.1	A cycle of phase-shifting stage table.	60
Table 4.1	The average of food intake during dry tank (FID) and weight	
	gain after dry tank(WGD) and food intake during wet tank	
	(FIW) and weight gain after wet tank (WGW) between PC and	
	REMsd groups.	88
Table 4.2	Overall EL time within all groups during MWM test for 5	
	days' acquisition for both experimental groups.	93
Table 4.3	Mean relative value of DREAM protein measured in nucleus	
	and cytoplasm in REMsd and CD experiments.	131
Table 4.4	Mean relative level of Tau and PHF proteins and the PHF/Tau	
	ratio.	133

LIST OF FIGURES

Figure 2.1	Stages of sleep.	5
Figure 2.2	Memory classification.	16
Figure 2.3	Mechanisms of LTP initiation	20
Figure 2.4	The limbic lobe.	25
Figure 2.5	The hippocampal formation.	27
Figure 2.6	The hippocampal circuit of trisynaptics loop.	29
Figure 2.7	Nuclear Magnetic Resonance structure of DREAM protein.	35
Figure 2.8	Tau protein.	38
Figure 2.9	The isoforms of Tau in human neurons.	40
Figure 2.10	Formation of PHF and NFT.	43
Figure 2.11	Water tank and equipment used in MWM test analysis.	49
Figure 3.1	Study flow chart for REM sleep deprivation experiment.	56
Figure 3.2	Study flow chart for circadian disruption experiment.	57
Figure 3.3	Rats in circadian disruption group.	59
Figure 3.4	Inverted flower pot technique for REM sleep induction.	64
Figure 3.5	Morris water maze tank (view from recording camera).	68
Figure 3.6	Steps in immunohistochemistry – Free-floating technique.	73
Figure 3.7	Gel for sample loading.	78
Figure 3.8	Semidry trans-blotting equipment.	81
Figure 3.9	Protein confirmation using Ponceau S solution.	81
Figure 4.1	Food consumption results dry tank.	86
Figure 4.2	Food consumption results wet tank.	86
Figure 4.3	Body weight (g) gain during 72 hours of adaptation period.	88
Figure 4.4	Body weight gain (g) during experimental period.	88
Figure 4.5	Serum melatonin level.	90
Figure 4.6	Daily escape latency (EL) for all groups in REM.	92

Figure 4.7	Daily escape latency (EL) for all groups in CD.	92
Figure 4.8	Probe test for REM.	95
Figure 4.9	Probe test for CD.	95
Figure 4.10	EL for reverse spatial for REM.	97
Figure 4.11	EL for reverse spatial for CD.	97
Figure 4.12	The hippocampal at 4x magnification.	99
Figure 4.13	DPN expression in hippocampus.	100
Figure 4.14	Mean DPN in REM sleep deprivation experiment.	101
Figure 4.15	Mean DPN in CD experiment.	101
Figure 4.16	PHF Tau staining in CA region of hippocampus.	104
Figure 4.17	Tau protein staining in CA region of hippocampus.	105
Figure 4.18	Mean TPN in REM sleep deprivation experiment.	106
Figure 4.19	Mean TPN in CD experiment.	106
Figure 4.20	Mean PPN in REM sleep deprivation experimen.	107
Figure 4.21	Mean rank score for PPN in CD experiment.	107
Figure 4.22	Mean rank score for PPN/TPN ratio in REM sleep deprivation.	108
Figure 4.23	Mean PPN/TPN ratio in CD experiment groups.	108
Figure 4.24	Mean relative DREAM protein levels of hippocampal nucleus	
	REM sleep deprivation experiment group.	110
Figure 4.25	Mean relative DREAM protein levels in hippocampal nucleus	
	of CD experiment group.	111
Figure 4.26	Mean relative PHF protein levels in hippocampal nucleus of	
	REM sleep deprivation experiment groups.	113
Figure 4.27	Mean relative PHF protein levels in hippocampal nucleus of	
	CD experiment groups.	114
Figure 4.28	Mean relative total Tau protein levels in hippocampal nucleus	
	in REM sleep deprivation experiment groups.	116
Figure 4.29	Mean relative Tau protein levels in hippocampal nucleus of	
	CD experiment group.	117
Figure 4.30	Mean relative PHF/Tau ratio in hippocampal nucleus of REM	
	sleep deprivation experiment groups.	119
Figure 4.31	Mean relative PHF/Tau ratio in hippocampal nucleus of CD	
	experiment groups.	119

Figure 4.32	Mean relative DREAM protein levels in hippocampal	
	cytoplasm of REM sleep deprivation experiment group	121
Figure 4.33	Mean relative DREAM protein in hippocampal cytoplasm of	
	CD experiment group.	122
Figure 4.34	Mean relative PHF Tau protein levels in hippocampal	
	cytoplasm of REM sleep deprivation experiment group	124
Figure 4.35	Mean relative PHF protein in hippocampal cytoplasm of CD	
	experiment group.	125
Figure 4.36	Mean relative Tau protein levels in hippocampal cytoplasm of	
	REM sleep deprivation experiment group	127
Figure 4.37	Mean relative Tau protein in hippocampal cytoplasm of CD	
	experiment group.	128
Figure 4.38	Mean relative PHF / total Tau protein ratio in hippocampal	
	cytoplasm of REM sleep deprivation experiment group.	130
Figure 4.39	Mean relative PHF/Tau ratio in hippocampal cytoplasm of CD	
	experiment group.	130
Figure 5.1	The summary of findings in the current study.	151

LIST OF APPENDICES

Appendix A	: Animal ethics approval
------------	--------------------------

Appendix B : List of materials used in this study

Appendix C : ELISA Steps

LIST OF ABBREVIATIONS

ACD	: Acute Circadian Disruption
AChE	: acetylcholinesterase
Αβ	: amyloid β peptide
ANOVA	: Analysis of variance
APS	: Ammonium persulphate
ARASC	: Animal research and service centre
BCA	: bicinchoninic acid
BDNF	: brain-derived neurotrophic factor
BF	: basal forebrain
BSA	: bovine serum albumin
BWg	: body weight gain
CA	: connus ammonis
CA1	: connus ammonis region 1
CA2	: connus ammonis region 2
CA3	: connus ammonis region 3
Ca ²⁺	: calcium
CaM	: calmodulin
cAMP	: cyclic adenosine monophosphate
Cav _{β3}	: a beta intracellular subunit of the voltage-gated calcium channel
CC	: Cage control
CCD	: Control Circadian Disruption
CD	: Circadian disruption
Cdk5	: cyclin-dependent kinas
CHCD	: Chronic circadian disruption
CNS	: central nervous system
CRE	: cAMP-responsive element
CREB	: cyclic AMP response element binding protein
DAB	: diaminobenzidine
DG	: dentate gyrus
dH ₂ O	: deionised water

DNA	: deoxyribonucleic acid
DPN	: DREAM positive neuron
DRE	: downstream response element
DREAM	: downstream regulatory element antagonist modulator
DT	: distance travelled
EC	: entorhinal cortex
EEG	: electroencephalogram
EF1	: first EF hand
EF2	: second EF hand
EF3	: third EF hand
EF4	: fourth EF hand
EL	: escape latency
ELISA	: enzyme linked immunosorbent assay
EMG	: electromyogram
ER	: endoplasmic reticulum
ETC	: electron transport chain
Fc	: food consumption
GA	: Golgi apparatus
GABA	: gamma-aminobutyric acid
GlcNAc	: β-N-acetylglucosamine
Glu	: glutamate
GLUT	: glucose transport system
H_2O_2	: hydrogen peroxide
HCl	: hydrochloric acid
HRP	: horseradish peroxidase
IDV	: integrated density values
IgG	: immunoglobulin G
IHC	: immunohistochemistry
K^+	: potassium
KChIPs	: voltage-gated potassium (Kv) channels-interacting proteins
Kv	: voltage-gated potassium
LD	: Light: Day

LTD	: long term depression
LTP	: long term potentiation
МАРК	: mitogen- activated protein kinase
mPRF	: medial pontine reticular formation
mRNA	: messenger RNA
MS	: medial septum
MWM	: Morris water maze
n	: number
Na ²⁺	: sodium
Na ₂ HPO ₄	: disodium hydrogen phosphate
Na ₂ HPO ₄ .7H ₂ O	: sodium phosphate heptahydrate
NaCl	: sodium chloride
NaH ₂ PO ₄ .H ₂ O	: sodium dihydrogen phosphate dehydrate
NaHCO ₃	: sodium bicarbonate
NaOH	: sodium hydroxide
NCS	: Neuronal Calcium Sensor
NCX2	: sodium-calcium exchange 2
NEPER	: nuclear protein extraction
NGS	: normal goat serum
NMDA	: N-methyl-D-aspartate
NPY	: neuropeptide Y
NREM	: non-rapid eye movement
NT	: neurotrophin
OD	: optical density
PAGE	: polyacrylamide gel electrophoresis
PB	: phosphate buffer
PBS	: phosphate buffered saline
PC	: Pedestal control
PFA	: paraformaldehyde
PHF	: Paired helical filament
РКА	: protein kinase A
РКС	: protein kinase C

POMC	: pro-opiomelanocortin
PPN	: Positive PHF Neuron
PS	: paradoxical sleep
PSD-95	: post synaptic dendrite -95
PT	: probe test
R	: rapid eye movement group
REM	: Rapid Eye Movement
REMsd	: REM sleep deprivation
RER	: rough endoplasmic reticulum
RN	: rapid eye movement and nicotine treated group
RNA	: ribonucleic acid
rpm	: revolutions per minutes
S.E.M	: standard error mean
SDS	: sodium dodecyl sulphate
SDS-PAGE	: sodium dodecyl sulphate polyacrylamide gel
SPSS	: statistical package of social sciences software
SWS	: slow wave sleep
TBS	: tris buffer saline
TBS-T20	: tris buffer saline-Tween 20
TBS-TX	: tris buffer saline- Triton X-100
TEM	: transmission electron microscopy
TEMED	: N,N,N'N'-tetramethylenediamine
TF	: Transcription factor
TPN	: Tau Positive Neuron
Zt	: Zeitgeber

KESAN KEKURANGAN TIDUR PADA MEMORI, PENGHASILAN PROTEIN DREAM DAN FOSFORILASI BERLEBIHAN PROTEIN TAU KE ATAS TIKUS

ABSTRAK

Ritma sirkadian dikawal selia oleh biologi dalaman yang mengawal aktiviti fisiologi yang berbeza termasuk kitaran sel, suhu badan dan metabolisma badan. Pemantapan memori berlaku semasa fasa tidur yang dinamakan 'rapid eye movement' (REM), jadi apabila ritma sirkadian terganggu dan juga fasa REM ini terganggu, memori akan turut terjejas. Protein yang dinamakan Downstream regulatory element antagonist modulator (DREAM) didapati memberi kesan kepada pembelajaran dan memori. Proses fosforilasi Tau protein yang berlebihan akan menyebabkan ketidakstabilan pada fungsi sel neuron dan akan mempengaruhi proses pembelajaran. Kajian ini bertujuan untuk mengkaji kesan gangguan tidur dan sirkadian (circadian *disruption* - CD) pada memori. Seratus empat puluh empat ekor tikus Sprague Dawley telah digunakan dalam kajian ini. Dalam eksperimen CD, gangguan sirkadian akut (acute circadian disruption - ACD) telah dilakukan dengan mengawal ritma sirkadian pada tikus ACD tiga jam awal dari hari sebelumnya. Gangguan ini telah dilakukan selama 6 hari diikuti oleh 10 hari rehat (re-entrainment). Proses yang sama telah diulang selama empat kali dalam kajian gangguan sirkadian kronik (chronic circadian disruption - CHCD). Pada kumpulan lain, pengurangan tidur fasa REM telah laksanakan dengan meletakkan mereka pada platfom kecil di dalam tangki berisi air (kumpulan REMsd). Kumpulan kawalan REMsd (PC) telah dimasukkan ke dalam keadaan yang sama seperti kumpulan REMsd kecuali mereka telah diletakkan di atas

platform yang lebih luas di mana mereka dapat tidur dan berehat dengan baik. Kumpulan kawalan dalam sangkar (CC) telah dimasukkan ke dalam sangkar biasa. Ia diikuti oleh ujian Morris water maze (MWM) untuk menilai kebolehan memori berkenaan ruang (*spatial*), platform tersembunyi (*probe*) dan ruang secara berbalik (reverse spatial). Kemudian, otak tikus bahagian hipokampus telah dikeluarkan dan nukleus serta sitoplasma neuron diekstrak untuk protein DREAM, Tau dan Tau terfosforilasi dianalisa dengan kaedah pewarnaan immunohistochemistry (IHC) dan *Western Blot* (WB). Ujian MWM mengukur tempoh masa untuk tikus berenang untuk mencari platform (EL) dari setiap kumpulan. Tempoh perbezaan EL selama lima hari didapati tidak berbeza secara signifikan (p> 0.05) di antara semua kumpulan dalam eksperimen REMsd tetapi didapati signifikan lebih lama pada kumpulan ACD dalam eksperimen CD. Ujian probe untuk MWM menunjukkan perbezaan yang tidak signifikan (p> 0.05) di antara kumpulan dalam eksperimen REMsd dan CD. Ujian mengukur memori secara berbalik juga menunjukkan perbezaan yang tidak signifikan di antara semua kumpulan (p> 0.05) dalam eksperimen REMsd dan CD. Ekspresi protein DREAM menunjukkan tiada perbezaan secara statistik direkodkan di antara kumpulan dalam eksperimen REMsd dan CD. Protein Tau dan Tau terfosfolirasi didapati berbeza secara statistik di antara kumpulan REMsd dan CC (p <0.05) dan kumpulan ACD dan CCD (p<0.01) dalam eksperimen REMsd dan CD, tetapi tidak signifikan berbeza terhadap ekspresi protein Tau yang terfosfolirasi berlebihan. Manakala untuk analisis WB menunjukkan tahap protein DREAM secara relatifnya tidak signifikan berbeza di antara kumpulan dalam eksperimen REMsd dan CD. Purata relatif Tau terfosforilasi berlebihan adalah tidak mempunyai perbezaan statistik yang signifikan di antara kumpulan dalam eksperimen REMsd dan CD. Kesimpulannya, protokol yang digunakan dalam kajian ini tidak berjaya menghasilkan perubahan dari

segi tingkah-laku otak dan tahap ekspresi protein DREAM dan fosforilasi berlebihan protein Tau.

THE EFFECTS OF SLEEP DEPRIVATION ON SPATIAL MEMORY, DREAM AND HYPERPHOSPHORYLATED TAU PROTEINS EXPRESSION IN RATS

ABSTRACT

Circadian rhythm is regulated by an endogenous biological regulator controlling various physiological activities, including cell cycle, body temperature, and metabolism. Some consolidation of memory occurs during Rapid Eye Movement (REM) sleep, so when the circadian system breaks down and REM sleep depressed, the memory will be affected. Downstream regulatory modulator antagonist (DREAM) proteins were discovered to affects learning and memory, while Tau protein hyperphosphorylation indicates some degree of neuronal instability influencing learning processes. This study aimed to examine the effects of sleep and circadian disruption (CD) on memory. One hundred and fourty four Sprague Dawley rats were used in this study. In the CD experiment, acute circadian disruption (ACD) was induced by putting the rats on a three-hour phase advance method for 6 days followed by 10 days of re-entrainment. This cycle was induced four times in a chronic circadian disruption (CHCD) study. On the other hand, REM sleep deprivation was induced by putting the rats on a small platform in a water tank (REMsd group). The REMsd control group (PC) was placed in the same condition as the REMsd group except that they were put in a broader platform to sleep and relax (PC group). The free-moving control group (CC) was placed in normal propylene cages (CC group). It was followed by the Morris water maze (MWM) task to assess spatial, probe test, and reverse spatial test. Then, the rat's brain from the hippocampal region was removed. The neuron's nucleus and cytoplasm were extracted for DREAM, normal Tau, and phosphorylated

Tau protein expression analyses by Immunohistochemistry and Western Blot (WB) analysis. In MWM test, the mean daily escape latency was measured for all rats from each group. The differences of EL between the groups were not statistically significant (p > 0.05) when compared between all groups in REM and CD experimental groups. The probe test showed no statistically significant (p>0.05) difference between the groups in the REMsd and CD experiment. The reverse spatial trial showed no significant difference between all groups (p>0.05) in the REMsd and CD experiment. DREAM protein expression was not statistically significant difference between groups in the REMsd and CD experiment. Tau and phosphorylated Tau protein was found to be significantly different when compared between REMsd and CC groups (p<0.05) and ACD and CCD group in the REMsd and CD experiment, but not significant difference for hyperphosphorylated Tau protein expression. WB analysis showed that the mean relative DREAM protein level was not statistically significant between all REMsd and CD experiment groups. The mean relative groups in the hyperphosphorylated Tau difference also was found not statistically significant between groups in the REMsd and CD experiments. In conclusion, the current study protocol failed to adequately elicited significant changes in neurobehavioral and level of the DREAM and hyperphosphorylated Tau protein expression.

CHAPTER 1 INTRODUCTION

Learning and memory consolidation and sleep-dependent are one of the areas of interest in neuroscience. Many studies have shown the importance of sleep in memory consolidation, which is a crucial part of the learning process (Stickgold and Walker, 2005, Maquet, 2001, Smith, 1995). Rapid Eye Movement sleep stage (REM) is related to non-declarative memory consolidation, which is essential in learning a new skill related to the procedure (Rasch and Born, 2013).

Lifestyle has now been increasingly stressful; failure to manage it may be affecting the quality and quantity of sleep needed. Furthermore, the arrival of portable touchscreen devices which are widely used in online social interaction and essential in fitting the needs of excellent work performance might worsen the situation of sleep quality. Studies have shown the sleep duration has become less, and the onset of sleep has become longer due to difficulties of falling asleep, as observed among high school and college students. These are the stages where learning is an essential part of their life (Peach et al., 2015).

Active learning induces neuronal excitation in the brain cortex. During sleep, neuronal excitation will be transferred to the inner part of the brain. This process will firmly consolidate the memory (Ngo and Staresina, 2017, Marshall and Born, 2007, Stickgold and Walker, 2005; BuzsÁk, 1998). This explains briefly and superficially how sleep in learning and memory are interrelated.

1.1 Rationale of The Study

Therefore, the current study aimed to explore the effects of REM sleep deprivation and circadian rhythm disruption on learning and memory by investigating the behavioural analysis and brain proteins measurement.

1.2 General Objective

The general objective is to measure the expression and level of DREAM and hyperphosphorylated Tau protein expression in REM sleep deprivation and circadian rhythm disruption in Sprague Dawley rats.

1.3 Specific Objectives

- 1.3.1 To evaluate the effects of REM sleep deprivation and circadian rhythm disruption on spatial memory in Sprague Dawley rats.
- 1.3.2 To measure DREAM and Hyperphosphorylated Tau proteins expression in Sprague Dawley rat's hippocampus after REM sleep deprivation and circadian rhythm disruption experiment.
- 1.3.3 To measure the level of DREAM/calsenilin and Hyperphosphorylated Tau protein expression in Sprague Dawley rat's hippocampus after REM sleep deprivation and circadian rhythm disruption experiment.

CHAPTER 2 LITERATURE REVIEW

Throughout all living organisms, sleep is a part of the most crucial cycle of their daily life. It carries a long list of physiological functions, and some of them are still elusive. Sleep deprivation affects many aspects of all living organisms. Sleep is not merely just a state of unconsciousness. It is defined as the behaviour of temporary perceptual disengagement from the external environment. However, from the inside, it involves a very complex physiological process and changes which carry all the essential function for human body revitalization before the next wake up cycle (Carskadon, 2011).

2.1 Sleep

A few physiological changes are associated with sleep. Physically, sleep dissociates a person from the environment, and it is associated with loss of consciousness. During sleep, the muscular hypotonic leads the postural changes to a recumbent position. Eye closure inhibits light entrance to the retina, thus cascading the sensory insensitivity in which its threshold gets higher as the sleep moves from arousal to deeper sleep stages (Datta, 2010).

2.1.1 Stages of Sleep, REM Sleep Versus NREM Sleep

Sleep can be divided into two stages: non-rapid eye movement (NREM, pronounced Non-REM) and rapid eye movement (REM). The classifications of various sleep stages are made based on the physiological parameters and brain wave activity recorded using an electroencephalogram (EEG). More than one cycle of NREM and REM sleep stages may occur throughout the night of a healthy individual. The mentioned two sleep cycles alternate cyclically. In a sleep disorder, the irregularity

of cycling and/or devoid of any cycle stage may occur (Altevogt and Colten, 2006). (Figure 2.1)



One sleep cycle

Figure 2.1: States of mind in awake and various sleep stages. There are four NREM stages, which move from light sleep to deeper sleep stage from one to four. After stage 4 is the REM sleep stage, where the states of mind resemble the awake and active stage. Adapted from Altevogt and Colten, 2006

A single sleep cycle consists of NREM, the initial stage, which is then followed by REM. The first cycle lasts for an average of 70 to 100 minutes, and the subsequent cycles are longer, with an average of 90 to 120 minutes per cycle. NREM sleep stage accounts for about 75 - 80% of the cycle, and 20 - 25% is the REM sleep stage (Altevogt and Colten, 2006).

NREM sleep is further subdivided into stages 1, 2, 3, and 4. This subdivision is based on the EEG pattern observed (Table 2.1 – NREM sleep stages brain wave). From the active brain wave during wakefulness to the alpha wave, an active but clam or resting stage of the brain in Stage 1 of NREM. Stage 1, which lasts for about seven minutes, is easily interrupted by noise. The second stage of NREM has a lower voltage of brain wave and the main difference from Stage 1 is the presence of the K wave complex and sleep spindle (Table 2.1). Stage 3 and 4 are collectively called slow-wave sleep (SWS). They have high voltage and slow activity brain waves. Stage 4 has a higher voltage wave, and it lasts longer than Stage 3. Brain waves in NREM sleep are well synchronised (Altevogt and Colten, 2006).

REM sleep cycle started when the brain waves desynchronised, with lowvoltage waves with mixed frequencies. The brain waves in a REM sleep cycle is described as having a sawtooth appearance. Along with the sawtooth brain waves activity, the muscles atonia and rapid eye movement occur in the REM sleep cycle. This stage lasts only for about one to five minutes during the initial cycle but getting longer in subsequent cycles. Unlike NREM sleep, REM sleep is not divided into any substages.

Dreaming is mostly associated with the REM sleep stage, during which the muscles atonia are important to avoid muscle actions during dreaming (Altevogt and Colten, 2006, Carskadon, 2011). Sleepwalking disorder is related to dreaming in the

latter two stages of NREM sleep, where the muscle tone is present (Guilleminault et al., 2006).

State of Brainwave Features mind Beta brain wave. Awake and active h Ml Awake and Alpha brain wave. drowsy Stage 1 of A mixture of alpha and theta waves. NREM Stage 2 of The appearance of NREM sleep spindle and Kcomplex in theta wave. mmunget the first annum Stage 3 of A mixture of theta and NREM delta wave. Stage 4 of Delta wave. NREM M REM Fast active brain Resembles wave. brainwave in active Sawtooth waves Sawtooth waves awake brain. mannermon

Table 2.1: Brainwaves in various states of mind and stages of sleep (Adapted from Altevogt and Colten, 2006).

8

2.1.2 Physiological Benefits of Sleep

Although the actual functions of sleep are elusive, there are a few theories and ongoing studies that have been done regarding the functions of sleep for the human body. Researchers are still working on a few hypotheses about the actual functions of sleep. They mentioned the hypothesis about energy conservation in sleep. Energy conservation is related to the release of specific genes regulated based on the circadian cycle that controls the food or energy released during sleeping (Sen et al., 2017, Schmidt et al., 2017). Meanwhile, brain metabolic down-regulation is related to the NREM sleep cycle, which is postulated to preserve and restore the brain glucose level during sleep. However, brain metabolism is higher during the wake-up stage of the REM sleep cycle; this indicates more neuronal excitation occurs during the REM sleep stage (Krueger et al., 2016). This explains how a daytime power nap that involves only Stage 1 and 2 of NREM sleep stages has a rejuvenating body effect (Hayashi et al., 2005).

Sleep helps in body recuperation after being affected by certain diseases by enhancing the immune systems (Krueger et al., 2016). One of the most interesting functions of sleep is how it is related to many aspects of brain wellness. For instance, cognitive impairment is related to poor sleep quality and sleep insufficiency. A study showed that sleep insufficiency in adolescents is related to more significant risk-taking behaviour due to poor cognitive judgment (Telzer et al., 2013). Good quality of sleep is crucial for emotional stability, proved by the amygdala's negative stimulation in the limbic system of a sleep-deprived person (Yoo et al., 2007). And for learning and memory benefits, sleep-associated neuroplasticity is currently being one of the major neuroscience fields. Neuroscientists are working out at the various levels of how sleep affects learning and memory.

2.1.3 Sleep-Wake – Regulating System

Some essential brain areas are involved in sleep-wake regulation. Four regions are located in the hypothalamus, one in pineal gland, and one region is in the brainstem. In the hypothalamus, there are suprachiasmatic nucleus (SCN), lateral hypothalamus, ventral preoptic nucleus and tuberomammillary nucleus. SCN is the region involved in sleep-wake homeostasis and is related to the circadian rhythm. Sleep homeostasis determines the amount of sleep needed. It is explained when a person has been awake for a longer duration, that person will have a stronger sleeping drive. In turn, the sleeping drive decreases after a period of sleep (Krystal et al., 2013). In the lateral hypothalamus, orexin, also known as hypocretin, is the neuropeptide involved in wakefulness. They start firing during the sleep-wake transition. Narcolepsy, a chronic sleep disorder is characterised by extreme daytime sleepiness, is associated with orexin deficiency (Krystal et al., 2013, Kalia, 2006, Krebs, 2012).

The ventrolateral preoptic (VLPO) nucleus of the hypothalamus is important for the slow-wave sleep oscillation, the NREM stages. Neurons in the VLPO nucleus are activated by adenosine and prostaglandin D2. The tuberomammillary nucleus of the hypothalamus, mediated by the histamine neurotransmitter, is essential in promoting wakefulness (Kalia, 2006). Hence this is explained when drowsiness is the effect of anti-histamine medication.

The suprachiasmatic nucleus (SCN) of the hypothalamus acts as a regulator for the endogenous biological clock by controlling the wake-sleep cycle known as the circadian rhythm. SCN is located at the anterior hypothalamus. It serves as a 'master clock' that controls both physiological and behavioural circadian rhythm. SCN is a neural substrate for day and night cycles in many physiological regulations, including motor activity, body temperature secretion of many hormones, sleep-waking, and many more (Gray, 2005, Krebs, 2012). SCN operated as a luminance detector when they received light input from the retina through retinothalamic fibres that terminate in SCN of the hypothalamus and regulate all physiological regulation based on it. The retinal ganglion cells' activation upon receiving light in the retina stimulates the melanopsin in the SCN. This triggers the sympathetic nervous system's activation in the thoracic region, leading to a negative feedback loop mechanism towards inhibition of melatonin released by the pineal gland (Kalia, 2006).

A region known as reticular formation has an ascending reticular activation system (ARAS) in the brainstem. This system has two pathways known to induce wakefulness. The deactivation of these pathways leading to sleep generating process. The pathways are the dorsal ascending pathway and the ventral ascending pathway. Fibres in the dorsal ascending pathway arise from the nuclei in the pons and medulla of the brainstem. They ascend towards the thalamic nuclei, and then they are projected to several parts of the brain cortex. Acetylcholine is the neuropeptide that mediates neuronal firing in this region during wakefulness and during the REM sleep stage. Fibres in the ventral ascending pathway arise from locus coeruleus, known as a noradrenergic neuron, while dorsal and median raphe nuclei are called serotoninergic neurons. They project toward the basal forebrain by passing by the lateral hypothalamus. Neurons of these fibres actively fire during wakefulness and not in REM sleep or REM sleep stages (Kalia, 2016). Lesions involving ARAS causes unconsciousness.

2.1.4 Neuromodulator for Wake-Sleep Cycle

Having known the regions involved in the sleep-wake regulating system, the neurotransmitter released by neurons in these regions is in charge of maintaining wakefulness or actively being released during sleeping. So, the neurons involved in maintaining wakefulness are called the wake-active neurons, and neurons that are released during sleep are called sleep-active neurons (Szymusiak and McGinty, 1989, Morairty et al., 2004). Noradrenaline, histamine, and orexin are the neurotransmitters released by the neurons categorized in the wake-active neurons. Their release is abundant during awake, reduced during SWS, and ceased during REM sleep. Acetylcholine in the same group as neurotransmitters above, being actively released during the wake and REM sleep stage but decreases during SWS. The neurons in the sleep-active category release GABAergic neurotransmitter. They are mainly found in the basal forebrain and preoptic (VLPO) of the hypothalamus and reciprocal to the wake-active neurons (Jones, 2005).

2.1.5 Sleep Initiation Process

A passive closure of the cerebral sensory gate leads to deafferentation. This quiet initiation of sleep shuts up all the excitatory event of all wake-active neurons in the ARAS and all regions involved in arousal. The neurons in the preoptic or anterior hypothalamus that contain inhibitory neurotransmitters influence the wake-active neurons. The deactivation of ARAS stopping the sensory impulse firing towards the cerebral cortex (Datta, 2010).

Another theory mentioned the accumulation of endogenous metabolites that facilitates the movement from wakefulness to sleep. This theory is based on the homeostatic regulation of sleep, which means the longer the awake period, the higher the metabolites accumulate. The known metabolites that initiate the SWS are adenosine, prostaglandin D2, neuroinhibitory amino acid GABA, cytokine (interleukin I beta), and tumour necrosis factor α (TNF α) (Datta, 2010, Datta and Maclean, 2007).

2.2 Circadian rhythm

2.2.1 The molecular event under the circadian rhythm regulation

An endogenous circadian clock controls the circadian rhythm. The study of genetic factors that influence the circadian rhythm was done a few decades ago. In 1988, they finally found the first clue to how our body controls the biological clock through a fruit fly study when they found a protein named period (PER). This protein was scattered throughout the fruit fly cells' nucleus in a profound amount during the night time than in the day time, and it shuttles between cytoplasm and nucleus. The PER mRNA was also circulating high at night, indicating PER level is high in the presence of increased mRNA PER and PER oscillation follow the day and night cycle (Saez and Young, 1988).

In 1995, they discovered another gene, timeless (TIM). TIM and TIM mRNA circulate in a circadian manner like PER. TIM directly reacts in PER by preventing degradation of PER in the day time. In humans, the oscillator of circadian rhythm is regulated by a transcription-translation feedback loop (TTFL) (Sehgal et al., 1994, Price et al., 1995).

PER and TIM proteins transcription are activated by another gene call clock (CLK) and cycle (CYC) genes. These two genes interact with each other in the PER gene and produce mRNA for PER. On the other hand, PER and TIM is the negative regulator for CLK and CYC genes, thus promoting a circadian feedback loop cycle (Jin et al., 1999).

Besides the CYC and CLK that activate PER, the degradation of PER is done by a protein kinase known as doubletime (DBT). DBT phosphorylates PER and degrades them. Meanwhile, the TIM protein degradation occurs by the interaction of TIM with cryptochrome (CRY) protein. CRY genes that interact with the TIM in the process of degradation of TIM are activated by light. That results in a gradual degradation of TIM as the morning arrives. On the other hand, leaving PER protein awaiting the time to be phosphorylated. The transcription and degradation of PER and TIM cycling followed the circadian rhythm and controlled the internal biological events of the organisms (Price et al., 1998, Jin et al., 1999).

2.2.2 Zeitgeber time

The exogenous factor that synchronises the organism's endogenous circadian rhythm is known as Zeitgeber. The factor can be a form of light, social and chemical. Zeitgeber time is a system that refers to the time in the period of Zeitgeber, for instance, the 12:12 light: dark cycle used in light factor Zeitgeber. The Zeitgeber time 0 (Zt 0) refers to the beginning of the light on, and ZT 12 is the beginning of the light off. (Daan and Merrow, 2002)

2.3 Memory

Memory is a part of learning where its quality is evaluated based on the performance of a person after a series of training. Memory involves the processes of data acquisition, consolidation, retention, retrieval, and performance at various stages and occurs at the cellular and molecular level of the human brain complex (Abel and Lattal, 2001). Memory acquisition happens during training, followed by up to a few days of memory consolidation and memory retrieval during re-training. Good memory consolidation is indicated by improvement in the last training session.

External sensory signals gain from learning or training will be received and transcribed in the brain cortex. The transcribed signal will then be transmitted to the hippocampus, where new memory formation occurs. After a strong or repeated signal transmission at the hippocampus, the recent memory is established. This memory is then wired back to the brain cortex for storage. Disorder of hippocampus structure and function lead to the inability to produce recent memory while they still have the storage of the old one.

2.3.1 Memory classification

Memory is subjected to different ways of classification. One of the most common ways is dividing it into two main prongs: declarative and non-declarative memory (Figure 2.2). Neuropsychologists defined this classification based on the involvement of the medial temporal lobe's region during memory acquisition. Declarative memory critically involves encoding at the brain's medial temporal lobe region during the memory acquisition process (Rasch and Born, 2013). Hippocampus located at the medial temporal lobe is where the new memory formation occurs. Meanwhile, the entorhinal, perirhinal, and parahippocampus are the areas of memory storage. Thus, declarative memory is also known as hippocampal-dependent memory (Squire et al., 2004). Declarative memory is further divided into episodic and semantic memory. Episodic memory is the memory of events, for instance, the memory of our first day in university, and semantic memory is the general knowledge or fact that we learn in school, like the capital city of certain countries. Non-declarative memory is regarded as an unconscious type. It is more for procedural kinds like how to ride a bicycle (Squire, 1992).



Figure 2.2: This figure depicted the classification of memory. Memory is classified as long and short-term memory. Long-term memory is further divided into declarative in the form of data or theory, while non-declarative is best explained as acquired skills.

2.3.2 Memory Stages

Memory processing involves three main stages, which are memory acquisition, memory consolidation, and memory retrieval. Memory acquisition is the stage where we gain new information or data from learning or training. Through a strong or effective way of the information or data collected, it will stay in our memory once it stabilised in storage, which is the brain cortex. The process of stabilisation is called the memory consolidation stage. Next is when we want to retrieve the information or data that we stored, we will recall the data from our memory. The latter is known as a memory retrieval stage.

2.3.3 Cellular and Molecular Level of Memory Formation

Neurons in the nervous system that connected at a small cleft are called a synapse. A typical neuron can have thousands of synapses connecting to other neurons. The connections work in an intricate manner that allows the brain to function normally. The synaptic connection can change over time. Following repeated stimulations, the connection can become more substantial, and it even may produce a new pair of synaptic connections. In the case of ignorance or without further stimulus, the synapse connection may weaken and eventually be lost. The ability of neurons to change the structure of their synaptic ends is known as neuronal plasticity. The established, recent memory is formed after a robust synaptic connection. The strength of the connection is measured by the level of excitability of the postsynaptic neurons. A strong through repeated and high-frequency stimulus strengthens the synaptic connection after some time. This is known as long term potentiation (LTP), a cellular basis of learning and memory. (Abel and Lattal, 2001)

LTP can occur at various locations in the brain. One of them being the hippocampus, where LTP in this site involves glutamate as their neurotransmitter.

Glutamate is the most common excitatory neurotransmitter in the central nervous system. Neurons with glutamate neurotransmitters are known as glutamatergic neurons. Stimulations of glutamatergic neurons lead to the action's potential travels down through its axon and glutamate releases at its synaptic end. Glutamates bind to the α -amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA) receptor and N-methyl-D-aspartate (NMDA) receptor at the postsynaptic neurons (Abel and Lattal, 2001).

When a weak signal is transmitted in the presynaptic neuron, it releases a small number of glutamates. Those glutamates will bind to both AMPA and NMDA receptors and allow AMPA receptors to influx cations, sodium (Na⁺), and no cations influx through NMDA receptors due to magnesium (Mg²⁺) blockage in the NMDA receptor channel. These amounts of Na⁺ produce weak depolarisation of the postsynaptic neuron. However, a strong signal will release many glutamates and allow more Na⁺ influx through the AMPA receptor. An adequate amount of Na⁺ allowed greater depolarisation of postsynaptic neurons, which removes the Mg²⁺ blockage of the NMDA receptor. When the NMDA channel opened, it will enable the influx of Na^+ and calcium (Ca^{2+}). Calcium is the mediator of LTP induction by initiating the signaling pathway that activating several protein kinases (Figure 2.3). Calcium/calmodulin-dependent protein kinase II (CaMKII) and protein kinase C (PCK) are two types of protein kinases in early LTP. In early LTP, those protein kinases phosphorylate the AMPA receptor increases the AMPA receptor conductions to sodium. Protein kinases help in bringing out more AMPA receptors from the intracellular storage to the postsynaptic membrane. This signal of early LTP is the basis of short-term memory, which lasts for several hours. In the late LTP phase, it involves new protein synthesis, which enhances the connection between pre and

postsynaptic neurons. It includes the synthesis of new AMPA receptors and proteins involved in the formation of new synaptic dendrites and synaptic connections. The late phase of LTP is the basis of long-term memory formation (Abel and Lattal, 2001).



Figure 2.3: Diagram of the molecular mechanism of Long Term Potentiation (LTP) initiation in neuronal plasticity. It is started with the strong or repeated impulse from the presynaptic neuron that releases the glutamate neurotransmitter. Those glutamates are then attached to the α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA) receptor, which results in the influx of sodium ions through the receptor. The increased concentration of sodium ion causes depolarisation and, at the same time, magnesium blockage at N-methyl-D-aspartate (NMDA) receptor was removed resulting in the influx of calcium ion and eventually initiate the LTP (Adapted from Abel and Lattal, 2001).

2.4 Sleep and Memory

Memory acquisition is an initial step in-memory processing. Acquisition of memory occurs during learning or training, and it relies on the integrity of the prefrontal cortex functions (PFC). Memory encoding is a process that occurs during the wake-up state. The deprivations of the pre-training sleep affecting the PFC metabolic rate, thus causing the memory acquisition difficulty (Walker and Stickgold, 2006). The cerebral metabolic rate is measured based on the oxygen level in the cerebral blood flow (Clarke, 1999). During SWS, the rate recorded slightly decreased than in the state of wakefulness but increased during the REM sleep stage (Madsen and Vorstrup, 1991, DiNuzzo and Nedergaard, 2017). While other researchers support that consolidation of memory is supported by sleep through various experiments (Ahrberg et al., 2012, Genzel et al., 2014). Post-training sleep stabilises newly obtained memory by increasing its resistance to interference (Ellenbogen et al., 2006). This allows this memory to stay longer before consolidation takes place. Sleeping after memory acquisition has better memory retrieval than wakefulness (Korman et al., 2007).

2.4.1 Roles of Sleep on Memory Consolidation

For more than a hundred years, scientists have established the importance of sleep in memory consolidation through thousands of research. Among those, the most acceptable finding is the ability to sleep to stabilize memory by increasing memory interference from external stimuli. From the results of REM sleep's involvement, they revealed the importance of SWS for the consolidation of memory. Memory acquisition allows the memory encoding process in the brain. During the SWS stage, optimisation of memory encoding occurs, and consolidation occurs during the REM sleep stage (Rasch and Born, 2013).

It is described that memory storage in declarative memory involved two standard storages: fast learning and slow learning storage. Fast learning store refers to the hippocampal that is engaged in new memory formation. A slow learning store is long-term memory storage located at the neocortex. Fast learning store receives new data and stores it temporarily in it. In other recent data, it encoded the previous data that may sometimes be unstable and easily disrupted by the new ones. So, because of sleep adequacy, pre-learning sleep is found to strengthen the fast learning storage center by making it more stable and resistant to deletion upon other data encoding.

On the other hand, going to sleep after learning makes the memory storage more stable before its projection to the slow learning storage after a certain learning period (Rasch and Born, 2013). To prove the importance of REM sleep in stabilising the newly stored memory, Davis et al., (2006) have studied REM sleep deprivation's effects on the up-regulation of cortactin, an important cytoskeleton in neuronal plasticity. Their study confirmed the incidence of inhibition of up-regulation of the cortactin, which leads to interference of LTP in rats and the whole process in memory consolidation (Davis et al., 2006).

2.4.2 Molecular Modulator for LTP in Memory Consolidation

A few molecules and proteins are critically crucial for the modulation of LTP in hippocampal-dependent memory consolidation processes. They are the brainderived neurotrophic factor (BDNF), cAMP response-element-binding (CREB), and calcium–calmodulin-dependent protein kinase II (CAMKII). These molecules involve in many directions of strengthening synaptic plasticity.

BDNF is a growth factor for neurons in the nervous system. Thus, it is known as a neurotrophic factor. BDNF, translated from the chromosome in the human brain, binds to tyrosine kinase B (TrkB) and low-affinity nerve growth factor receptor (LANGF) before eliciting their action, neuronal growth, and maturity. BDNF is crucial for the growth and survival of dopaminergic, GABAergic, serotoninergic, and cholinergic neurons, which are important for neuronal excitatory (Pillai, 2008). In the LTP signaling process, BDNF in the presynaptic neurons enhances the release of neurotransmitters. Meanwhile, in postsynaptic neurons, they increase the influx of calcium and potassium ion through enhancing the ion channels in NMDA receptors and eventually helps in the initiation of LTP through the early and late phase of LTP (Poo, 2001, Lu et al., 2008) cited by (Autry and Monteggia, 2012).

CREB is a cellular transcription factor that binds to DNA and influences the up-regulation or down-regulation of certain genes. BDNF gene is one of the genes that CREB regulates. A previous study that involved the disruption of the CREB gene leads to impairment of long-term memory formation (Bourtchuladze et al., 1994). CREB involve in molecular cascades mediating the transformation of short-term memory to long-term memory. They influence synaptic plasticity during long term memory consolidation. Besides, it is also found that they increase neuronal excitability (Benito and Barco, 2010). As mentioned in LTP cellular mechanism, CREB is a factor that is opening the gate for protein phosphatases that is important in maintaining the influx of sodium through AMPA receptor for induction of powerful depolarisation, cascading for the LTP initiation (Blitzer et al., 1995).

CAMKII is a protein kinase that regulates the calcium/calmodulin complex. It is involved in many cellular signaling cascades, and one of them is in learning and memory. Regulation of this protein kinase induces protein phosphorylation is a catalyst for various intracellular LTP induction changes in a neuron. The intracellular function includes neurotransmitter synthesis, cytoskeletal functions, gene expression, synaptic plasticity and all process involved in LTP (Yamauchi, 2005).

2.5 Circadian Rhythm and Memory

The circadian rhythm is controlled by a central pacemaker, the SCN of the anterior hypothalamus, is associated with the hippocampal formation. Hippocampus is critical in learning and memory, integrating the circadian information through direct or indirect input from SCN or other oscillators input, modulating the hippocampal neurogenesis through clock genes expression and genetic modification. (Smarr et al., 2014, Ruby et al., 2008). A study concluded that the memory impairment in circadian rhythm disruption is associated with inhibition of GABAergic communication to the hippocampus (Ruby et al., 2008). Clock gene expression in the hippocampus, which is rhythmically oscillated postulated to be synchronised by SCN (Smarr et al., 2014). These clock genes then regulate the hippocampus's neurogenesis (Gery et al., 2006, Matsuo et al., 2003). Melatonin is an endogenous hormone released based on the circadian clock, where its levels are higher during the dark phase, promoting neuron maturation and survival (Ganguly et al., 2002).

2.6 Hippocampus and Memory

The cerebral cortex is the largest part of the brain, which contains lobes that include the limbic lobe. The limbic lobe, located at deep brain area is also known as the medial temporal lobe in the cerebral hemisphere's medial wall. The limbic lobe is made of subcallosal (corpus callosum), cingulate and para-hippocampal gyri (Figure 2.4).